• Reported revenues of €2.2 billion represent an increase of €417 million (23.2%) on 2018 • Operating income of €424 million represents an increase of €78.6 million (22.7%) on 2018 • All products performed well, but highlights are the year-on-year growth of the Group’s immunoglobulin product portfolio, as well as …
أكمل القراءة »